The upgraded Coronavirus vaccine developed by Moderna showed a strong response to the Omicron variant, better than the previous version of the vaccine, Reuters cited a study on Wednesday.
The study was conducted by the company and targeted using the developed vaccine as booster shots against Coronavirus in the upcoming weeks.
Moderna's new vaccine is not only directed to Omicron but also to the original strains of the virus.
Moderna Official Stephen Bancel said: "We anticipate more durable protection against variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster."
On his side, an epidemiologist at Johns Hopkins School of Public Health David Dowdy reflected: “I would be cautiously optimistic that this bivalent vaccine will be at least a little more effective against Omicron than the original vaccine, but it’s far too early to talk about it being any sort of game-changer."
Last April, the US drugmaker announced it had submitted a request for an emergency use approval for its COVID-19 vaccine for children ages ranging between 6 months and 6 years.
Moderna’s Chief Executive, Stephane Bancel, said in a statement: “We believe [this vaccine] will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID -19 and will be especially welcomed by parents and caregivers.”
On the other hand, leading drug-makers Pfizer and BioNTech submitted a request to get the approval of the Food and Drug Authority (FDA) for booster shots for children between 5 and 11.
The request from the drug-makers came after a new study showed that the booster shots could give children strong immune response against COVID-19.
The booster dose will be given to children six months after receiving the essential doses.